ASTRAZENECA PLC-SPONS ADR (AZN)       65.53  -0.46 (-0.7%)

65.53  -0.46 (-0.7%)

US0463531089 - ADR - Premarket: 66.36 +0.83 (+1.27%)

ASTRAZENECA PLC-SPONS ADR65.53

NASDAQ:AZN (1/27/2023, 7:00:00 PM)-0.46 (-0.7%)

Premarket: 66.36 +0.83 (+1.27%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Pharmaceuticals

Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend

Overview
Earnings (Last) 11-10 2022-11-10/bmo Earnings (Next) N/A N/A
Ins Owners N/A Inst Owners 16.86%
Market Cap 203.12B Shares 3.10B
PE 18.72 Fwd PE 17.02
Dividend Yield 1.98% Analysts 79.49
IPO 09-21 2007-09-21

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

AZN Daily chart

Company Profile

AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. The company is headquartered in Cambridge, Cambridgeshire and currently employs 83,100 full-time employees. The company went IPO on 2007-09-21. The firm focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Its pipeline forms a robust portfolio of investigational therapies in various stages of clinical development. Its pipeline includes the Alexion Rare Disease portfolio and comprises approximately 179 projects. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its BioPharmaceuticals products include Farxiga, Lokelma, Crestor, Breztri and others. Its geographical segments include United Kingdom, Rest of Europe, The Americas and Asia, Africa & Australasia. The company is also focused on discovering, developing, and manufacturing of T-cell receptor therapies.

Company Info

ASTRAZENECA PLC-SPONS ADR

1 Francis Crick Avenue

Cambridge CAMBRIDGESHIRE CB2 0AA

P: 442073045000.0

CEO: Pascal Soriot

Employees: 83100

Website: https://www.astrazeneca.com/Home

AZN News

News Imagea day ago - The Motley FoolCould This Vaccine Become Sanofi's Latest Blockbuster?

This vaccine candidate could be approved in newborns and infants later this year.

News Image3 days ago - The Motley FoolCould This Be Novartis' Next Blockbuster Medicine?

The Swiss drugmaker recently shared promising phase 3 clinical trial results for this rare-disease drug.

News Image3 days ago - InvestorPlace7 Dividend Stocks to Buy for a Stable Income Stream

These are the dividend stocks to buy for a regular income stream and potential capital gains as these stocks trade at attractive valuations.

News Image4 days ago - Seeking AlphaAZN stock dips as FDA pulls EUA for AstraZeneca COVID-19 antibody (NASDAQ:AZN)

The FDA announced Thursday that Evusheld, a COVID-19 antibody therapy developed by AstraZeneca (AZN), is no longer authorized in the U.S. due to lack of efficacy. Read the full story here.

News Image4 days ago - MarketBeatMergers and Acquisitions in 2023 Off To A Strong Start

Mergers and acquisitions are common, especially across the health sector. Here are some lesser-known buyouts and how they could fare down the road.

News Image4 days ago - The Motley FoolIs Johnson & Johnson Still a Good Dividend Stock to Buy?

A disappointing fourth-quarter performance has some investors worried about the giant healthcare conglomerate's outlook.

AZN Twits

Here you can normally see the latest stock twits on AZN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example